Lab-Grown tumor models could personalize mesothelioma care

NCT ID NCT07330271

Recruiting now Disease control Sponsor: Beijing Tsinghua Chang Gung Hospital Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 18, 2026 · Updated 22 times

Summary

This study is for adults with malignant peritoneal mesothelioma (MPM), a rare cancer in the lining of the abdomen. After surgery, doctors usually give standard chemotherapy, but it's hard to know which drug will work best. This trial tests a new approach: growing a mini tumor model from the patient's own cancer in the lab, testing different drugs on it, and then giving the patient the drug that works best on their model. About 347 participants will be randomly assigned to either standard chemotherapy or this personalized treatment. The goal is to see if the personalized approach helps people live longer without their cancer getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERITONEAL MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tsinghua University affiliated Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, 102218, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PERITONEAL MESOTHELIOMA